Back to Newsroom

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

SAN DIEGO, June 25, 2015 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (POLT) recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection and have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR).

Click here to read more